Abstract
Glioma remains incurable despite great advancements in medicine. Targeting the cell of origin for gliomas could bring great hope for patients. However, as a collection of diverse diseases, each subtype of glioma could derive from a distinct cell of origin. To resolve such a complex problem, one must use multiple research approaches to gain deep insights. Here we review current evidence regarding the cell of origin from clinical observations, whole-genome molecular pathology and glioma animal models. We conclude that neural stem cells, glial progenitors (including oligodendrocyte progenitor cells) and astrocytes could all serve as cells of origin for gliomas, and that cells incurring initial mutations (cells of mutation) might not transform, while their progeny cells could instead transform and act as cells of origin. Further studies with multidisciplinary approaches are needed to link each subtype to a particular cell of origin, and to develop effective therapies that target the signaling network within these cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 383-394 |
| Number of pages | 12 |
| Journal | Expert Review of Molecular Diagnostics |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - May 2012 |
Keywords
- animal model
- astrocyte
- cell of mutation
- cell of origin
- cell-targeted therapy
- malignant glioma
- molecular pathology
- neural stem cell
- oligodendrocyte progenitor cell
- tumor subtype
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Molecular Medicine
- Molecular Biology
- Genetics
MD Anderson CCSG core facilities
- Bioinformatics Shared Resource
Fingerprint
Dive into the research topics of 'The cellular origin for malignant glioma and prospects for clinical advancements'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS